Devices, Systems and Methods for Ophthalmic Drug Delivery
First Claim
Patent Images
1. A method of delivering one or more drugs to an ocular tissue, comprising:
- implanting a drug source into a human or animal;
implanting a terminal component into an ocular tissue of the human or animal, the terminal component being in fluid communication with the drug source; and
delivering one or more drugs from the drug source to the ocular tissue through the terminal component.
1 Assignment
0 Petitions
Accused Products
Abstract
Devices, systems and techniques for delivering drugs to an ocular tissue are described. In at least some embodiments, a terminal component (e.g., a needle or open end of a catheter) is implanted in an ocular tissue and used to deliver one or more drugs. The delivered drugs may come from a source which is also implanted, or may be introduced from an external source (e.g., via a port). Both solid and liquid drug formulations can be used. Ocular implants can alternatively include a thin film coating that releases a drug into an ocular tissue.
-
Citations
32 Claims
-
1. A method of delivering one or more drugs to an ocular tissue, comprising:
-
implanting a drug source into a human or animal; implanting a terminal component into an ocular tissue of the human or animal, the terminal component being in fluid communication with the drug source; and delivering one or more drugs from the drug source to the ocular tissue through the terminal component. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
-
25. A method of fabricating solid pellets of gacyclidine base, comprising:
-
neutralizing a conjugate acid form of the gacyclidine base in solution with a pharmaceutically acceptable base, and subjecting a suspension resulting from the neutralizing step to centrifugal force. - View Dependent Claims (26, 27)
-
-
28. A method, comprising:
applying gacyclidine to an ocular tissue to treat at least one of ocular tissue trauma, macular degeneration, vein occlusion, ischemia, diabetic retinopathy, neurodegeneration, and retinal damage resulting from exposure to intense light energy.
-
29. A method of delivering one or more drugs to an ocular tissue, comprising:
-
implanting a subcutaneous port in a human or animal; implanting a terminal component into an ocular tissue of the human or animal, the terminal component being in fluid communication with the subcutaneous port; placing the implanted subcutaneous port into fluid communication with a pump or other fluid source located external to the human or animal; and delivering one or more drugs from the pump or other fluid source to the ocular tissue through the implanted terminal component.
-
-
30. A method of delivering one or more drugs to an ocular tissue, comprising:
implanting in an ocular tissue an implant having a thin film coating that includes a neuroprotective agent. - View Dependent Claims (31, 32)
Specification